Analysis of the mechanism of action of elacestrant and its specific application in cancer treatment

Elacetrant (Elacestrant) is a new oral selective estrogen receptor degrader (SERD). Its main target is estrogen receptor α (ERα). It binds to estrogen receptors with high affinity, not only inhibiting receptor activation, but also promoting receptor degradation, thus blocking the driving effect of estrogen signaling pathways on tumor cells. This mechanism is different from traditional tamoxifen or aromatase inhibitors. Traditional drugs mainly inhibit tumors by competitively inhibiting estrogen binding or reducing estrogen levels in the body. However, elastran can directly cause receptor degradation, significantly reduce the content of receptors in the nucleus, and exert a more comprehensive anti-tumor effect.

In breast cancer treatment, estrogen receptor-positive (ER+) breast cancer patients account for the vast majority, especially postmenopausal women. By degrading ERα, elastran causes tumor cells to lose estrogen-dependent signals and prevents tumor proliferation and metastasis. Clinical studies have shown that elastran is still effective in patients with ER+ breast cancer who have developed resistance after previous treatment with aromatase inhibitors or tamoxifen, which provides a new treatment option for drug-resistant patients. In addition, the oral administration of elastran facilitates long-term maintenance treatment and improves patients' quality of life. Compared with injectable SERD, it is more in line with patients' long-term management needs.

In addition to single-agent use, elastran also shows potential in combination therapy. For example, in clinical trials, the combined use of elastran with CDK4/6 inhibitors can further block tumor cell cycle progression and enhance the anti-tumor effect. Combination therapy is particularly important for patients with advanced or recurrent ER+ breast cancer, because these patients are often resistant to endocrine therapy, and combination therapy can delay the emergence of resistance and improve progression-free survival (PFS). A number of ongoing multi-center clinical studies are also evaluating the effect of combining elastran with PI3K inhibitors or mTOR inhibitors, hoping to provide personalized treatment options for patients with different molecular subtypes of breast cancer.

In clinical application, elastran is well tolerated, and common adverse reactions include nausea, fatigue, joint pain, and mild bone marrow suppression, most of which are controllable mild to moderate reactions. This allows patients to maintain quality of life during long-term maintenance treatment. In addition, for patients with severe liver function abnormalities or underlying cardiovascular diseases, a comprehensive evaluation is required before use to ensure safety. Taken together, through its unique mechanism of action, elastran provides a new treatment idea for ER+ breast cancer, especially drug-resistant patients. Both single drug and combined application show good clinical prospects, and may become an important choice for endocrine therapy for drug-resistant breast cancer in the future.

Reference materials:https://www.drugs.com/